US-based Warburg Pincus in talks to buy Maneesh Pharma unit in Rs 1,800 crore deal

US private equity firm Warburg Pincus is nearing a deal to buy Maneesh Pharmaceuticals' non-tuberculosis drug business. The acquisition is valued between ₹1,600 to ₹1,800 crore. This move is part of Warburg's strategy to build a larger pharmaceutical platform in India. A formal announcement is anticipated in the coming months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/J6oL8TN
via IFTTT

Read More

Rising costs of key chemicals choke production at drug ingredient makers

India's bulk-drug manufacturers are facing a severe cost crisis as prices of key solvents and intermediates have surged due to supply disruptions linked to the West Asia conflict. This has led to production halts for several units, with paracetamol API prices more than doubling, impacting the entire pharmaceutical value chain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JsMpRqy
via IFTTT

Read More

Centre steps up oversight on GLP-1 drugs amid concerns over 'improper' practices

India's drug regulator is increasing oversight of GLP-1 weight loss drugs. Inspections across 49 entities revealed violations like unauthorized sales and improper prescriptions. Strict actions, including license cancellation, will be taken against non-compliant firms. An advisory also prohibits misleading advertisements. These medications should only be used under qualified medical guidance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YFaK8JV
via IFTTT

Read More

India tightens grip on GLP-1 supply chain amid misuse concerns, expands crackdown on unapproved drugs

India's drug regulator is increasing checks on weight loss drug sales. This action follows inspections of pharmacies and clinics nationwide. The goal is to prevent illegal sales of these specialized medicines. Authorities are also cracking down on unapproved drug combinations. Patient safety is the top priority as regulators enforce rules across the pharmaceutical supply chain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RS4iu8U
via IFTTT

Read More

GST refund stress: MedTech sector flags cash crunch, seeks relief

India's medical device sector is facing severe financial strain, prompting an urgent plea to the government for expedited GST refund processing. Delays in refunds from last year's rate reduction, coupled with rising input costs due to the West Asia conflict, have created significant working capital distress.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xhkNyF1
via IFTTT

Read More

India’s drug regulator flags 90 unapproved FDCs, directs states to take action

India's drug regulator has initiated a nationwide crackdown on unapproved fixed-dose combination drugs. At least 90 such medicines have been identified. States are directed to take immediate action against manufacturers, marketers, and distributors. This move follows lab testing data analysis. The Drugs Controller General of India emphasizes zero tolerance to protect public health and safety.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x7SGmTb
via IFTTT

Read More

Price alone won't push weight-loss, diabetes drug semaglutide sales: Doctors

Leading drugmakers including Sun Pharmaceuticals, Dr Reddy’s Laboratories, Zydus Lifesciences, Natco Pharma, Eris Lifesciences, USV, Glenmark, and Torrent were among the first to roll out generic semaglutide on the first day of patent expiry of Novo Nordisk’s innovator molecule on Saturday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/my3X8YP
via IFTTT

Read More